Healthcare Investment Opportunities You Can't Miss

HENDERSON, NV / ACCESSWIRE / February 13, 2019 / When looking for great growth opportunities to invest in, look no further than the healthcare sector. Healthcare stocks have consistently produced big winners in recent years, and the future looks even brighter.

One that's on top of our radar is, Endonovo Therapeutics, Inc. (ENDV). The company has several non-invasive therapies tackling everything from pain management to degenerative joint diseases. The company just announced a deal that will add up to $10 million in working capital to their balance sheet which could amplify the company's already rapid growth. At its current price now is a perfect time to research ENDV.

We are highlighting: Endonovo Therapeutics, Inc. (ENDV), Outlook Therapeutics, Inc. (OTLK), CorMedix, Inc. (CRMD), 22^nd Century Group, Inc. (NYSE American: XXII), and Zynerba Pharmaceuticals, Inc. (ZYNE).

The global market for non-opioid pain treatment totaled $9.9 billion in 2017 and is estimated to reach $22.6 billion by 2022, growing at a CAGR of 18.0% for the period of 2017-2022. The aforementioned Endonovo Therapeutics, Inc. (ENDV) (Market Cap: $11.79M Share Price: $0.024), a commercial-stage developer of non-invasive wearable Electroceuticalsâ„¢ Therapies, has developed a therapy that could help lessen the pain without the kinds of side effects many other opioid alternatives have. Their non-invasive easy to use ORTHOHALOâ„¢ device delivers targeted Pulsed ElectroMagnetic Field (tPEMF) therapies to reduce pain and enhance post-surgical recovery, naturally. Its patented non-pharmacologic process uses proprietary technology to reduce pain, swelling, and inflammation.

The company just released a shareholder letter, in it there is a list of the company's latest accomplishments. The list below is impressive and is a big reason why the company is starting a major rally.

Highlights include:

• Signing two marketing agreements with well-established medical device sales organizations
• Establishment and expansion of a rapidly growing sales department
• The completion of the purchase price to the seller of the SofPulse Technology
• The new Roma medical device is on schedule for release in Q1 of 2019

ENDV announced an agreement with Azure Capital that will bring the company up to $10 Million for general corporate purposes, including working capital. This is a major development that could expedite the company's growth.

ENDV also just filed a patent infringement lawsuit today in the U.S. District Court for the Central District of California against KVP INTERNATIONAL, INC., a California Corporation, ORTHOCOR MEDICAL, INC., a Delaware Corporation, and CAERUS CORP., a Minnesota Corporation. The lawsuit states the aforementioned companies make, market, import, use, sell, and/or offer for sale several products and related services within the United States which infringe Endonovo's Patents. This could add even more capital to the company's bottom line.

Start your research on ENDV.

____

Outlook Therapeutics, Inc. (OTLK) (Market Cap: $98.31M Share Price: $1.09) recently announced that it closed on the final tranche (of four) of its $20.0 million private placement of common stock to BioLexis Pte. Limited (BioLexis), the Company's strategic business partner and largest investor, receiving $4.0 million of cash proceeds in exchange for the issuance of 4,288,624 shares of common stock at $0.9327 per share.

____

CorMedix, Inc. (CRMD) (Market Cap: $37.70M Share Price: $2.07) announced the topline results of the full data set of the Company's Phase 3 LOCK-IT-100 study for Neutrolin® as a catheter lock solution in hemodialysis patients. The Company recently announced the topline results from the interim analysis of the study, which was terminated in August 2018 following the recommendation of the independent Data Safety Monitoring Board (DSMB), because efficacy had been demonstrated and the pre-specified level of statistical significance had been achieved.

____

22^nd Century Group, Inc. (XXII) (Market Cap: $276.17M Share Price: $2.22) submitted a Modified Risk Tobacco Product (MRTP) application with the U.S. Food and Drug Administration (FDA) for the Company's Very Low Nicotine Content (VLNC) cigarettes. 22nd Century's proposed VLNTM cigarettes, the subject of the MRTP application, are made with the Company's proprietary VLNTM tobacco and, as a result, contain very low levels of nicotine.

____

Zynerba Pharmaceuticals, Inc. (ZYNE (Market Cap: $102.06M Share Price: $5.79) released 12-month clinical data that describes the lifelong impact of ZYN002 on developmental and responsive symptoms of Fragile X syndrome. In a poster for the presentation in the 57th annual meeting, Professor Steven Siegel gives the presentation of the 12-month data of the second phase of the clinical trial of […] The post Zynerba Gives Clinical Update, Lifelong Impact Of ZYN002 appeared first on Market Exclusive.